Why Eli Lilly Stock Flopped Today
We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of their value during the big market sell-off that day, and it wasn't only because of the general gloom. That drop compared rather unfavorably to the relatively light 2.7% swoon of the S&P 500 (SNPINDEX: ^GSPC).
That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).
That morning, Wegovy maker Novo Nordisk announced the latest clinical trial results for an advanced obesity drug it's developing, CagriSema. Participants treated with CagriSema achieved weight loss of 15.7% after the 68-week duration of the trial. The drug seemed to have demonstrated a safe, well-tolerated profile.
Although Novo Nordisk described this result as "superior," it was well short of the 25% weight loss that the company had anticipated. Investor hopes were similarly high, so it's little wonder those folks were bearish on Novo Nordisk. They also punished fellow obesity drug developers like Eli Lilly in a sympathy sell-off.
I don't think investors in either company should give up because of these results. The weight loss drug segment is still quite new, and there will be many fits and starts by developers.
Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the market. Besides, the American pharmaceutical king has many other products currently on pharmacy shelves, and a wide and active pipeline.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $292,207!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $45,326!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $480,568!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
Continue »
*Stock Advisor returns as of March 10, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
Why Eli Lilly Stock Flopped Today was originally published by The Motley Fool
Sign in to access your portfolio
EMEA Tribune is not responsible for this news, news agencies have provided us this news.
Follow us on our WhatsApp channel here .
